The Division of Rheumatology strives to understand more about gout through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
|Brief Description||Basic Eligibility Criteria||Contact|
A Phase 4, Multicenter, Open-Label, Infusion Duration Study To Assess
Christopher Striebich M.D., Ph.D
|This study Assesses Safety, Tolerability and Efficacy of Pegloticase Administered With a Shorter Infusion|
Duration in Subjects with Uncontrolled Gout Receiving Methotrexate
1. Adult men or women ≥18 years of age.
1. Current or chronic treatment with systemic immunosuppressive agents such as MTX, azathioprine, or mycophenolate mofetil; prednisone ≥10 mg/day or equivalent dose of other corticosteroid on a chronic basis (defined as 3 months or longer) would also meet exclusion criteria.
2. Prior treatment with pegloticase (KRYSTEXXA), another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug.
3. Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product.
4. Contraindication to methotrexate (MTX) treatment, MTX treatment considered inappropriate, or know intolerance to MTX.
5. Uncontrolled hyperglycemia with a plasma glucose value >240 mg/dL at Screening that is not subsequently controlled by the end of the Screening.
6. Non-compensated congestive heart failure or hospitalization for congestive heart failure or treatment for acute coronary syndrome (myocardial infarction or unstable angina) within 3 months of the Screening Visit, or current uncontrolled arrhythmia, or current uncontrolled BP (>160/100 mmHg) prior to Week -4.